Explore resources for TRUTAKNA
Learn more about [TRUTAKNA] and support shared decision-making
HCP resources
TRUTAKNA HCP Brochure
Patient resources
Video library
Organizations for IgAN*
The IgA Nephropathy Foundation is dedicated to finding a cure for IgAN and works to fund research, provide advocacy, and build a support network for those living with IgAN.
The National Kidney Foundation (NKF) is an organization dedicated to providing education for kidney health and support for those living with kidney diseases.
NephCure is working to improve access to care for people with rare, protein-spilling kidney diseases, including IgAN, through research, advocacy, and community-building.
*
This is a partial list of advocacy organizations. Vera Therapeutics does not endorse any of the above organizations.
Request a TRUTAKNA representative
Learn more about this first-in-class treatment for IgAN by requesting to connect with a [TRUTAKNA] representative
Stay in the know about TRUTAKNA
Sign up to receive the latest on TRUTAKNA. These updates are intended for US healthcare professionals only
IgAN=immunoglobulin A nephropathy.
Support for your patients begins with Tru Support enrollment
There are 2 ways to enroll:
1
CoverMyMeds Portal
- If you do not already have an account, visit www.CoverMyMeds.health to create an account
- Search for [TRUTAKNA], and select Start Enrollment
- Carefully read and complete the form
- When complete, select Submit Enrollment Form
2
Fax
Download the enrollment form, and fax the completed document to 800-903-0428
Visit website.com for additional information about getting your patients started on [TRUTAKNA]
Resources at a glance
Insurance coverage assistance
Get help navigating the health insurance process for TRUTAKNA, including benefits verification and information regarding prior authorization, reauthorization, denials, and appeals
Financial resources
For eligible patients, help with accessing potential financial and coverage support options may be available
Patient support and resources*
Treatment administration education and resources may be provided by dedicated Nurse Educators throughout your patients’ treatment journeys with TRUTAKNA
Potential financial assistance options
Tru Support Copay Program†
Eligible commercially insured patients may pay as little as $0 out of pocket for TRUTAKNA.
Subject to annual maximum benefit. Restrictions apply.
Patient Assistance Program‡
Through the Patient Assistance Program, patients who are uninsured or underinsured may be eligible to receive TRUTAKNA at no cost.
Restrictions apply.
Tru Support Bridge Program§
If patients have delays with insurance coverage, the Tru Support Bridge Program may be able to offer temporary access to TRUTAKNA.
Restrictions apply.
For questions or additional assistance with coordinating patient access for TRUTAKNA, contact a Tru Support Case Manager or Field Reimbursement Manager.
800-729-8591, Monday–Friday, 8 AM–8 PM EST
Access coverage resources for TRUTAKNA
Tru Support Brochure
Tru Support Enrollment Form
Prior Authorization Checklist
Sample Letter of Appeals Template
Sample Medical Necessity Letter
*
Nurse Educators provide education and support related to therapy initiation, administration, and available patient assistance resources. They do not provide clinical care or offer medical advice. All treatment decisions are determined by the healthcare provider.
†
Program is only valid for patients with commercial or private insurance. Patient must be a US resident. Program is not valid for patients insured by a federal or state government-funded health plan, including Medicare, Medicare Advantage, Medicaid, and TRICARE. Program is void where prohibited by law. Program does not cover the costs of any other healthcare provider charges or any other treatment costs. Patients are responsible for non–drug-related out-of-pocket costs. Additional eligibility requirements may apply. Vera Therapeutics reserves the right to terminate or modify this program at any time without notice.
‡
To qualify for the Patient Assistance Program, patients must complete an application, be a resident of the United States or of a US territory, have a valid prescription for [TRUTAKNA], have no coverage/not enough coverage or insurance that doesn’t cover [TRUTAKNA], meet annual household income threshold based on household size, and agree to and provide income verification. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, or any state, patient foundation, or other pharmaceutical program.
§
Bridge Program is not health insurance and is available for eligible, commercially insured patients only. Patient must be a US resident. No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer, additional insurer, or a patient’s state-sponsored commercial insurance. Not available to patients covered by a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs, or Department of Defense or TRICARE programs. Bridge Program may be dispensed after primary coverage has been attempted and the patient is experiencing a delay in coverage. Available in a 28-day supply. Refills are subject to limitations and dispensing is at the sole discretion of Vera Therapeutics. To be eligible for an additional 28-day refill, the patient must be actively pursuing coverage through their insurance. Additional eligibility criteria may apply.
IMPORTANT SAFETY INFORMATION AND INDICATION
INDICATION
[TRUTAKNA] (atacicept) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether [TRUTAKNA] slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
[TRUTAKNA] is contraindicated in patients with a known hypersensitivity to atacicept-xxxx or any excipients of [TRUTAKNA].
WARNINGS AND PRECAUTIONS
Infections
Infections were reported in 32% of [TRUTAKNA] patients compared with 28% of placebo patients. The most common (>5%) infections reported were respiratory tract infections (12%) and nasopharyngitis (8%), which were mild or moderate in severity.
Delay [TRUTAKNA] administration in patients with any clinically important active infection until the infection resolves or is adequately treated.
In patients with chronic infection or history of recurrent infection, consider the risks and benefits prior to prescribing [TRUTAKNA]. Patients who develop a new infection while undergoing [TRUTAKNA] treatment should be monitored closely. Consider interrupting [TRUTAKNA] therapy if a patient develops a serious infection.
Immunizations
Prior to initiating [TRUTAKNA], complete all age-appropriate immunizations in agreement with current immunization guidelines. Patients on [TRUTAKNA] may receive concurrent vaccinations, except for live vaccines.
ADVERSE REACTIONS
The most common (≥5%) adverse reaction was injection site reactions.
Drug Interactions
Concomitant use of [TRUTAKNA] and:
• other immune-modulating therapies in patients with IgAN have not been evaluated.
• drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.
USE IN SPECIFIC POPULATIONS
Pregnancy
Available data on [TRUTAKNA] used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Atacicept-xxxx is known to cross the placenta of animals. In embryo-fetal development studies in mice and rabbits, no fetal malformations were observed. Females of childbearing potential should use effective contraception while receiving [TRUTAKNA].
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.
Please see Important Safety Information throughout and Full Prescribing Information here.
References: 1. TRUTAKNA. Prescribing information. Vera Therapeutics; 2026. 2. Floege J, Barratt J, Cook HT, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4):548-554. doi:10.1016/j.kint.2025.04.003 3. Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45. doi:10.36469/001c.26129 4. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. doi:10.3389/fneph.2023.1346769 5. Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71. 6. Lafayette R, Barbour SJ, Brenner RM, et al; ORIGIN Phase 3 Trial Investigators. A phase 3 trial of atacicept in patients with IgA nephropathy. N Engl J Med. 2026;394(7):647-657. doi:10.1056/NEJMoa2510198
